^
    1d
    Breast Conserving Therapy is a Safe Option for Women Under 40 Diagnosed With Breast Cancer. (PubMed, J Surg Res)
    In our cohort with 5-y survival data, BCT is a safe option for women aged 40 y and under who are diagnosed with breast cancer. Despite no survival benefit, young women with breast cancer in our cohort underwent mastectomy more often than lumpectomy. Importantly, most recurrences were distant metastases, suggesting that local therapy choice is less relevant to outcome.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HR positive • EGFR negative
    2d
    Breast cancer staging for patients with "low-risk" disease: Are they all the same? (PubMed, Cancer)
    Prognostic stage significantly influences survival among patients with low RS. RS < 11 alone should not automatically downstage patients to PPS IA; anatomic and other nongenomic factors remain important for prognosis.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    2d
    Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer. (PubMed, NPJ Breast Cancer)
    Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HR positive • HER-2 expression • HER-2 underexpression • AR positive
    2d
    EBNK-ST-001: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=83, Recruiting, Essen Biotech
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV
    2d
    SELECT-CAR-NK: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Essen Biotech
    New P1/2 trial • Liquid biopsy
    |
    cyclophosphamide • fludarabine IV
    2d
    A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer (clinicaltrials.gov)
    P1/2, N=285, Recruiting, Genentech, Inc. | Trial completion date: Jul 2030 --> Aug 2028 | Trial primary completion date: Jul 2030 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • giredestrant (RG6171) • RGT-419B
    2d
    Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=189, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    docetaxel • Verzenio (abemaciclib) • cyclophosphamide • epirubicin • Inluriyo (imlunestrant)
    2d
    Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy (clinicaltrials.gov)
    P=N/A, N=300, Enrolling by invitation, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    3d
    ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Laura Huppert, MD, BA | Trial completion date: Mar 2029 --> Jun 2029 | Trial primary completion date: Mar 2029 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HR negative
    |
    anvatabart opadotin (JNJ-0683)
    3d
    ELUCIDATE: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=230, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | N=165 --> 230
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    HR positive
    |
    Avastin (bevacizumab) • paclitaxel • capecitabine • fulvestrant • REC-617
    3d
    Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=4, Terminated, Jennifer Lee Caswell-Jin | Phase classification: P1b --> P1
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
    3d
    A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Hoffmann-La Roche
    New P2 trial
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation
    |
    Kisqali (ribociclib) • fulvestrant • Itovebi (inavolisib)